Gilead Sciences, Inc. (GILD)
- Previous Close
65.27 - Open
65.50 - Bid 65.37 x 800
- Ask 65.50 x 800
- Day's Range
64.64 - 66.35 - 52 Week Range
64.63 - 87.87 - Volume
12,348,617 - Avg. Volume
7,428,992 - Market Cap (intraday)
81.577B - Beta (5Y Monthly) --
- PE Ratio (TTM)
14.54 - EPS (TTM)
4.50 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 3.08 (4.71%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
83.88
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
www.gilead.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GILD
Performance Overview: GILD
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GILD
Valuation Measures
Market Cap
81.50B
Enterprise Value
99.22B
Trailing P/E
14.54
Forward P/E
15.38
PEG Ratio (5yr expected)
0.67
Price/Sales (ttm)
3.04
Price/Book (mrq)
3.57
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
9.45
Financial Highlights
Profitability and Income Statement
Profit Margin
1.77%
Return on Assets (ttm)
10.43%
Return on Equity (ttm)
2.39%
Revenue (ttm)
27.45B
Net Income Avi to Common (ttm)
485M
Diluted EPS (ttm)
4.50
Balance Sheet and Cash Flow
Total Cash (mrq)
4.72B
Total Debt/Equity (mrq)
147.93%
Levered Free Cash Flow (ttm)
12.39B
Research Analysis: GILD
Company Insights: GILD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GILD
Analyst Report: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
RatingPrice TargetAnalyst Report: Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.
RatingPrice TargetMarket Digest: TSM, TFC, GILD, OMC, VZ
We've reported for weeks that the trading activity among corporate insiders in general, but on the tech-heavy Nasdaq in particular, was clearly suggesting that stocks likely had come too far, too fast. Further, insider-sentiment data from Vickers Stock Research left the clear impression that stocks were priced for perfection and vulnerable to events like inflation disappointment, geopolitical turmoil, or less-than-expected corporate earnings. Now, a mix of all those things seem to be in play and stocks are indeed experiencing rough sledding for the first time since about October. Reflecting the forecasting from Vickers, as of this writing the Nasdaq Composite and Nasdaq 100 have slid about 7% from the March 22 highs while the S&P 500 is off about 5%.
The Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But the tide turned in 2022. The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.